Pfizer Canada Inc.

Pfizer Canada Inc.

May 17, 2012 07:54 ET

XYNTHA Solofuse Now Available in Canada for Patients with Hemophilia A

XYNTHA Solofuse brings to Canadian patients a new way to reconstitute their recombinant factor VIII, without a transfer step, all in one syringe.

XYNTHA Solofuse also offers a new 3000 IU dosage strength with the same 4 mL diluent.

KIRKLAND, QUEBEC--(Marketwire - May 17, 2012) -

Editors Note: There is a photo associated with this press release.

Pfizer Canada is pleased to announce the launch of XYNTHA Solofuse, the first device in Canada preloaded with recombinant factor VIII and diluent, indicated for the control and prevention of hemorrhagic episodes, and routine and surgical prophylaxis in patients with hemophilia A.i XYNTHA Solofuse is used to deliver XYNTHA by intravenous (IV) infusion after reconstitution of a freeze-dried powder with diluent (0.9% Sodium Chloride), eliminating the transfer step during reconstitution.i

"XYNTHA is a factor VIII recombinant product for patients with hemophilia A," said Diane Bissonnette, RN, BScN. "Every patient has different needs and expectations and although they may not have a choice of being born with the disease, they do have a choice in the availability of treatments adapted to their needs."

Albumin (a protein in blood plasma) free, XYNTHA Solofuse is available in 1000, 2000 and 3000 International Unit (IU) strengths.ii XYNTHA Solofuse can be connected to an R2 vial adapter to provide intermediate doses and allows the combination of multiple dosage strengths.

"Patients often inquire about the different reconstitution devices available so that they can select one that is a good fit for their lifestyle," says Elizabeth Paradis, Nurse Coordinator, Hemophilia Program at Health Sciences North in Sudbury. "XYNTHA Solofuse gives patients another option to consider."

About Hemophilia A

Hemophilia A (factor VIII deficiency) affects 1 in 10,000 people or about 2500 Canadians. It is a rare, inherited bleeding disorder caused by a mutation of the factor VIII protein.iii

In Canada, there are comprehensive care clinics that provide medical services needed by persons with bleeding disorders and their families. The comprehensive care team consists of a hematologist, nurse coordinator, physiotherapist and social worker with specific expertise in managing the healthcare needs of persons with bleeding disorders.

Pfizer is committed to the advancement of science in the treatment of hemophilia and is now the only manufacturer offering recombinant treatment solutions for both hemophilia A and B with XYNTHA and BeneFIX™ - Nonacog alfa (recombinant coagulation factor IX).i

About Pfizer Canada

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, one of the world's leading biopharmaceutical companies. The company is one of the largest contributors to health research in Canada. Our diversified health care portfolio includes biologic and small molecule medicines and vaccines for humans and animals, and many of the world's best-known consumer products.

Every day, Pfizer Canada employees work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything Pfizer does, from our disease awareness initiatives to our community partnerships, to our belief that it takes more than medication to be truly healthy.

To learn more about Pfizer's More than Medication philosophy and programs, visit To learn more about Pfizer Canada, visit

i Bayer. (2011). Kogenate FS Product Monograph. Toronto, Ontario: Bayer.
Behring. (2010). Helixate FS Product Monograph. Ottawa, Ontario: Behring.
Baxter. (2010). Advate Product Monograph. Mississauga, Ontario: Baxter.
ii Pfizer. (2011). Xyntha Solofuse Product Monograph. Kirkland, Quebec: Pfizer.
iii Canadian Hemophilia Society. (2012). What is hemophilia. Retrieved from Canadian Hemophilia Society Website:

To view the photo associated with this press release, please visit the following link:

Contact Information